Form 13-F position report

SPYRE THERAPEUTICS INC

Reported by PERCEPTIVE ADVISORS LLC

SYRE CUSIP 00773J202 Manager CIK 0001224962

Reported 3,280,943 shares, down 1,038,553 (24.0%) from the prior quarter.

Reported value -23.8%; share count -24.0% vs. the prior quarter.

Reduced
% of reported 13F value 5.09% This manager · Q3 2026
Shares 3,280,943 Quarter-end amount reported
Reported value $292,102,355 Fair value at quarter end
Consecutive quarters held 13 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-09-30 993671
2023-12-31 56095732
2024-03-31 96974834
2024-06-30 71259233
2024-09-30 84481607
2024-12-31 59939551
2025-03-31 37324644
2025-06-30 22895792
2025-09-30 20605498
2025-12-31 100547811
2026-03-31 190825869
2026-06-30 383484855
2026-09-30 292102355

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for SPYRE THERAPEUTICS INC held by PERCEPTIVE ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 3,280,943 -1,038,553 (-24.0%) 5.09% $292,102,355 2026-11-16
Q2 2026 Added 4,319,496 +536,271 (14.2%) 5.76% $383,484,855 2026-08-14
Q1 2026 Added 3,783,225 +714,000 (23.3%) 3.73% $190,825,869 2026-05-15
Q4 2025 Added 3,069,225 +1,839,780 (149.6%) 1.79% $100,547,811 2026-02-17
Q3 2025 Reduced 1,229,445 -300,000 (-19.6%) 0.6% $20,605,498 2025-11-14
Q2 2025 Reduced 1,529,445 -783,827 (-33.9%) 0.85% $22,895,792 2025-08-14
Q1 2025 Reduced 2,313,272 -261,451 (-10.2%) 1.32% $37,324,644 2025-05-15
Q4 2024 Reduced 2,574,723 -297,824 (-10.4%) 1.65% $59,939,551 2025-02-14
Q3 2024 Reduced 2,872,547 -158,471 (-5.2%) 1.79% $84,481,607 2024-11-14
Q2 2024 Added 3,031,018 +474,339 (18.6%) 1.72% $71,259,233 2024-08-14
Q1 2024 Reduced 2,556,679 -50,000 (-1.9%) 1.7% $96,974,834 2024-05-15
Q4 2023 Added 2,606,679 +2,525,563 (3113.5%) 1.25% $56,095,732 2024-02-14
Q3 2023 New 81,116 +81,116 (0.0%) 0.03% $993,671 2023-11-14

Who else reported the position

330 managers reported SPYRE THERAPEUTICS INC for Q3 2026.

Managers reporting SPYRE THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 13,496,596 +470,409 0.05% $1,201,601,942 12 qtrs
BlackRock Inc Added 6,779,486 +272,881 < 0.01% $603,577,615 9 qtrs
Paradigm Biocapital Advisors LP Added 4,457,450 +616,672 7.89% $396,846,774 9 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 4,063,789 +1,733,691 0.02% $361,799,135 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 3,750,793 +302,112 < 0.01% $333,933,101 3 qtrs
RTW INVESTMENTS LP Reduced 3,691,791 -560,205 3.31% $328,680,153 12 qtrs
STATE STREET CORPORATION Added 3,533,862 +476,446 < 0.01% $314,608,605 11 qtrs
PERCEPTIVE ADVISORS LLC This report Reduced 3,280,943 -1,038,553 5.09% $292,102,355 13 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 3,036,950 +76,095 0.03% $270,381,000 11 qtrs
JANUS HENDERSON GROUP PLC Added 2,894,015 +1,237,851 0.11% $257,756,249 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
3,280,943
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.